Profile
Sector:
HealthcareCountry:
United StatesIPO:
25 June 2021Website:
http://www.teknova.comNext earnings report:
11 March 2025Last dividends:
N/ANext dividends:
N/APrice
after hours | Sat, 16 Nov 2024 00:34:48 GMTDividend
Analysts recommendations
Institutional Ownership
TKNO Latest News
Alpha Teknova, Inc. (NASDAQ:TKNO ) Q3 2024 Earnings Conference Call November 7, 2024 5:30 PM ET Company Participants Jennifer Henry – Senior Vice President-Marketing Stephen Gunstream – President and Chief Executive Officer Matt Lowell – Chief Financial Officer Conference Call Participants Chad Wiatrowski – TD Cowen Lucas Baranowski – KeyBanc Capital Markets Vidyun Bais – BTIG Jacob Johnson – Stephens Matt Larew – William Blair Operator Hello, and welcome to Alpha Teknova Third Quarter 2024 Financial Results. At this time all participants are in a listen-only mode.
HOLLISTER, Calif., Oct. 24, 2024 (GLOBE NEWSWIRE) -- Alpha Teknova, Inc. (“Teknova”) (Nasdaq: TKNO), a leading producer of critical reagents for the discovery, development, and commercialization of novel therapies, vaccines, and molecular diagnostics, today announced that the Company will report its financial results for the third quarter ended September 30, 2024, on Thursday, November 7, 2024, following the close of market.
Does Alpha Teknova (TKNO) have what it takes to be a top stock pick for momentum investors? Let's find out.
Second quarter 2024 total revenue was $9.6 million, up 3% sequentially Raised $15.4 million of equity capital in July 2024 Launched two new offerings: Express-TekSM Production and RUO+ manufacturing grade Company reaffirms 2024 revenue guidance of $35-38 million
HOLLISTER, Calif., July 30, 2024 (GLOBE NEWSWIRE) -- Alpha Teknova, Inc. (“Teknova”) (Nasdaq: TKNO), a leading producer of critical reagents for the discovery, development, and commercialization of novel therapies, vaccines, and molecular diagnostics, today announced that the Company will report its financial results for the second quarter ended June 30, 2024, on Tuesday, August 13, 2024, following the close of market.
HOLLISTER, Calif., July 12, 2024 (GLOBE NEWSWIRE) -- Alpha Teknova, Inc. (“Teknova”) (Nasdaq: TKNO), a leading producer of critical reagents for the discovery, development, and commercialization of novel therapies, vaccines, and molecular diagnostics, today announced the closing of its previously announced private placement for the issuance and sale of an aggregate of 12,385,883 shares of its common stock at a purchase price of $1.24 per share. The private placement was priced based on the Nasdaq Official Closing Price of Teknova's common stock on July 11, 2024.
HOLLISTER, Calif., July 11, 2024 (GLOBE NEWSWIRE) -- Alpha Teknova, Inc. (“Teknova”) (Nasdaq: TKNO), a leading producer of critical reagents for the discovery, development, and commercialization of novel therapies, vaccines, and molecular diagnostics, today announced that it has entered into a definitive agreement for the issuance and sale of an aggregate 12,385,883 of its shares of common stock in a private placement at a purchase price of $1.24 per share. The private placement was priced based on the Nasdaq Official Closing Price of Teknova's common stock on July 11, 2024.
Second quarter 2024 total revenue is in the range of $9.4 to $9.6 million Company reaffirms 2024 revenue guidance of $35-38 million HOLLISTER, Calif., July 09, 2024 (GLOBE NEWSWIRE) -- Alpha Teknova, Inc. (“Teknova” or the “Company”) (Nasdaq: TKNO), a leading producer of critical reagents for the discovery, development, and commercialization of novel therapies, vaccines, and molecular diagnostics, today provided a business update including preliminary unaudited financial results for the second quarter ended June 30, 2024.
Alpha Teknova (TKNO) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.
Alpha Teknova (TKNO) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
What type of business is Alpha Teknova?
Alpha Teknova, Inc. produces critical reagents for the research, discovery, development, and commercialization of novel therapies, vaccines, and molecular diagnostics in the United States and internationally. The company offers pre-poured media plates for cell growth and cloning; liquid cell culture media and supplements for cellular expansion; and molecular biology reagents for sample manipulation, resuspension, and purification. It provides lab essentials which provides chemical formulations for use in biological research and drug discovery; and clinical solutions, a custom product used in the development and production of protein therapies, gene therapies, mRNA vaccines, and diagnostic kits. The company serves its products to life sciences market, including pharmaceutical and biotechnology companies, contract development and manufacturing organizations, in vitro diagnostic franchises, as well as academic and government research institutions. Alpha Teknova, Inc. was founded in 1996 and is headquartered in Hollister, California.
What sector is Alpha Teknova in?
Alpha Teknova is in the Healthcare sector
What industry is Alpha Teknova in?
Alpha Teknova is in the Drug Manufacturers - Specialty & Generic industry
What country is Alpha Teknova from?
Alpha Teknova is headquartered in United States
When did Alpha Teknova go public?
Alpha Teknova initial public offering (IPO) was on 25 June 2021
What is Alpha Teknova website?
https://www.teknova.com
Is Alpha Teknova in the S&P 500?
No, Alpha Teknova is not included in the S&P 500 index
Is Alpha Teknova in the NASDAQ 100?
No, Alpha Teknova is not included in the NASDAQ 100 index
Is Alpha Teknova in the Dow Jones?
No, Alpha Teknova is not included in the Dow Jones index
When was Alpha Teknova the previous earnings report?
No data
When does Alpha Teknova earnings report?
The next expected earnings date for Alpha Teknova is 11 March 2025